New hope for tough blood cancers? early trial launches
NCT ID NCT06037018
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 31 times
Summary
This early-stage study tests a new drug called CC312 in 44 adults with certain blood cancers (like lymphoma or leukemia) that have returned or stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
InstituteHBDH
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.